FDA Brief

Warning letters Drugs

FDA warning letter to

Novel Laboratories, Inc. d.b.a LUPIN

High riskIssued Jun 11, 2021Posted Jun 29, 2021Office of Pharmaceutical Quality Operations Division I

FDA warned Lupin's Novel Laboratories over manufacturing violations including equipment cross-contamination and unvalidated temazepam capsules.

What happened

FDA inspected the Somerset, New Jersey facility from September 10 to November 5, 2020. Investigators found active drug residue on a tablet press and air duct that had been documented as clean, and found temazepam 15 mg and 30 mg capsules made with unvalidated process and equipment changes, with out-of-specification content uniformity results. FDA also cited inadequate quality-unit oversight and incomplete annual product reviews.

What FDA found

  1. The company failed to establish and follow adequate written procedures for cleaning and maintenance of equipment; FDA found active drug residue on a tablet press and air duct documented as clean.

    21 CFR 211.67(b)
  2. The company failed to establish adequate written procedures for production and process control; temazepam capsule manufacturing was transferred with unvalidated process and equipment changes and had out-of-specification content uniformity results.

    21 CFR 211.100(a)
  3. The quality unit did not adequately oversee cleaning validation limits or complete annual product reviews as required.

    21 CFR 211.22(d); 21 CFR 211.180(e)

What FDA wants

Provide a written response within 15 working days describing corrections, including testing reserve samples for cross-contamination, a retrospective cleaning assessment, corrective action plans, validation improvements, and quality-unit remediation. If corrective actions cannot be completed in 15 working days, state the reasons and schedule.

Who should pay attention

  • brands and distributors that buy finished drug products from Lupin or Novel Laboratories
  • patients taking temazepam capsules or other products made on shared equipment
  • quality teams managing shared equipment cleaning and process validation

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. SnugZ USA, Inc.

    SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.

    High risk
  2. Silgan Dispensing Systems

    Silgan Unicep Packaging was cited for manufacturing quality failures and unapproved new drugs after invalidated microbial tests and a fungal recall.

    High risk
  3. Bentley Laboratories LLC

    Bentley Laboratories LLC was cited for CGMP violations and for marketing unapproved acne drugs.

    High risk
  4. Stream2Sea, LLC

    FDA found Stream2Sea, an OTC drug maker in Bowling Green, Florida, released drug batches without finished-product testing, raw material identity testing, or validated cleaning.

    Medium